v3.26.3
Note 3 - Discontinued Operations
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

3.

Discontinued operations

 

On September 30, 2026 (the “Closing Date”), the Company completed the sale of all of its equity interests in BeyondSpring Ltd., as described below. Upon completion of the Sale, the Company lost control of, and deconsolidated, (i) BeyondSpring Ltd. and its consolidated subsidiaries, including Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”) and SEED Technology Limited (the “BVI Disposal Group”), and (ii) SEED Therapeutics Inc.(“SEED”) and its condensed consolidated subsidiaries (the “SEED Disposal Group”).

 

BVI Disposal Group

 

On September 28, 2026, the Company entered into a Share Purchase and Collaboration Agreement (the “SPCA”) with Bulin, then a majority-owned indirect subsidiary of the Company, and Biolin Investment Limited, a Hong Kong limited company and a non-related party (the “Investor”). Pursuant to the SPCA, the Company sold all of its equity interests in BeyondSpring Ltd., a BVI holding company, together with its direct and indirect subsidiaries and related investments, to the Investor. The Sale was completed on September 30, 2026. No cash consideration was payable to the Company. Under the SPCA, the noncash consideration for the Sale consists of the Investor’s obligation to conduct and complete the China portion of DUBLIN-4, the Company’s global Phase 3 trial of Plinabulin in combination with docetaxel, and to cause Bulin to take certain actions related thereto. These actions include using commercially reasonable efforts to enroll a target number of patients, as determined by the Company (the “Target Enrollment”), within three years following the Closing Date (the “Enrollment Period”). The Company identified the following rights as the substantive benefits it receives from this consideration:

 

 

i.

An exclusive, irrevocable, perpetual, non-terminable, transferable, sublicensable, fully paid-up and royalty-free license to the clinical data generated by Bulin from the China portion of DUBLIN-4, for use outside of mainland China, Hong Kong, Macau and Taiwan (collectively, “Greater China”), which the Company intends to include in an integrated global clinical dataset in support of its registration strategy for Plinabulin; and

 

 

ii.

The right to recover a proportional portion of the equity interests sold based on the enrollment shortfall, or all of such equity interests if the shortfall is 90% or greater, if Bulin does not achieve the Target Enrollment by the end of the Enrollment Period.

 

These rights are contingent because the clinical data did not exist at the Closing Date, and the amount and value of the data the Company will ultimately receive depend on future patient enrollment, trial conduct, and the generation and delivery of data during the Enrollment Period. The right to recover equity interests depends on the same enrollment outcome. The Company has elected to account for nonderivative contingent consideration as a gain contingency under ASC 450-30 (see Note 2). Because these contingencies had not been resolved as of September 30, 2026, no amount was included in the gain on the Sale, and no asset has been recognized. The Company will recognize the contingent consideration at fair value when a substantive contingency is resolved and the consideration is realized or realizable, such as upon delivery of clinical data or the determination of an enrollment shortfall, which will occur no later than the end of the Enrollment Period.

 

SEED Disposal Group

 

On December 13, 2024, the Company’s Board of Directors approved a divestiture plan to sell and transfer approximately 90% to 100% of the Company’s interests in SEED. The divestiture of SEED represents a strategic shift in the Company’s reallocation and optimization of available resources to pipelines with greater potential. Accordingly, the assets and liabilities of SEED were classified as held for sale as of December 31, 2025, and the results of operations of SEED have been reflected as discontinued operations for all periods presented.

 

On January 24, 2025, the Company entered into a Preferred Share Purchase Agreement with each of Winning View Investment Limited, FULL TECH CORPORATE DEVELOPMENT LIMITED and Mapfil Investment Limited (collectively, the “Purchasers”), as amended on February 17, 2025 (collectively, the “SEED Purchase Agreements”). Pursuant to the SEED Purchase Agreements, the Company agreed to sell a total of 8,333,637 Series A-1 Preferred Shares of SEED to the Purchasers at $4.25 per share, for aggregate cash proceeds of $35,418, in three closings. The Company determined that the three closings should be accounted for as a single transaction in accordance with ASC 810-10-40-6. The First Closing was completed on February 19, 2025, in which the Company sold 1,730,454 Series A-1 Preferred Shares for cash proceeds of $7,354 and recognized a gain on sale of subsidiary interests of $6,986 for the nine months ended September 30, 2025, calculated as the cash proceeds less the $368 adjustment to noncontrolling interests. In connection with the First Closing, the Company recorded a gain on the sale of subsidiary interests for the nine months ended September 30, 2025 as follows:

 

   

Gain recognized on

the First Closing

 
   

Nine months ended

September 30, 2025

 

Fair value of consideration received

  $ 7,354  

Less: Adjustments to noncontrolling interests (6.75% of the equity interests)

    368  

Gain on sale of subsidiary interests

  $ 6,986  

 

Immediately prior to the Sale, the Company owned approximately 38.03% of SEED on an as-converted basis, directly and indirectly through BVI Disposal Group and controlled SEED through its right to designate a majority of SEED’s Board of Directors. Accordingly, SEED was a consolidated subsidiary classified as held for sale through the Closing Date. Upon completion of the Sale on the Closing Date, the Company’s indirect interest in SEED held through BVI Disposal Group was transferred to the Investor. Following the Sale, the Company retained one common share of SEED and 7,885,545 Series A-1 preferred shares representing approximately 29.14% of SEED’s voting power on an as-converted basis, together with the right to elect two directors. These retained interests and rights do not provide the Company with control over SEED. The Company therefore deconsolidated the SEED Disposal Group on the Closing Date and remeasured its retained interests in SEED at their fair value of $18,373, which became the initial carrying amount of the investment. The Series A-1 Preferred Shares are accounted for under ASC 321 using the measurement alternative, and the ordinary share is accounted for under the equity method. See Note 5 – Long-term equity investment.

 

Financial information of discontinued operations

 

The following tables set forth the assets, liabilities, statement of operations, and cash flows of discontinued operations which were included in the Company’s condensed consolidated financial statements.

 

   

As of

 
   

December 31, 2025

   

September 30, 2026

 
           

(Unaudited)

 

Assets

               

Current assets:

               

Cash and cash equivalents

  $ 9,171     $ -  

Short-term investments

    7,306       -  

Advances to suppliers

    239       -  

Prepaid expenses and other current assets

    26       -  

Total current assets

    16,742       -  
                 

Noncurrent assets:

               

Property and equipment, net

    1,384       -  

Operating right-of-use assets

    2,710       -  

Other noncurrent assets

    426       -  

Total noncurrent assets

    4,520       -  
                 

Total assets

  $ 21,262     $ -  
                 

Liabilities and equity

               

Current liabilities:

               

Short-term loans

  $ 4,369     $ -  

Accounts payable

    468       -  

Accrued expenses

    3,178       -  

Current portion of operating lease liabilities

    443       -  

Deferred revenue

    2,001       -  

Other current liabilities

    919       -  

Total current liabilities

    11,378       -  
                 

Noncurrent liabilities:

               

Operating lease liabilities

    1,945       -  

Deferred revenue

    30,421       -  

Other noncurrent liabilities

    3,891       -  

Total noncurrent liabilities

    36,257       -  
                 

Total liabilities

  $ 47,635     $ -  

 

   

Three months ended September 30,

   

Nine months ended September 30,

 
   

2025

   

2026

   

2025

   

2026

 
   

(Unaudited)

   

(Unaudited)

   

(Unaudited)

   

(Unaudited)

 
                                 

Revenue

  $ 501     $ 2,822     $ 1,501     $ 3,822  
                                 

Operating expenses

                               

Research and development

    (2,728 )     (2,645 )     (8,392 )     (9,060 )

General and administrative

    (1,170 )     (1,664 )     (3,063 )     (4,820 )
                                 

Loss from operations

    (3,397 )     (1,487 )     (9,954 )     (10,058 )

Foreign exchange gain, net

    23       447       93       559  

Interest income

    36       1       151       11  

Other income, net

    40       24       153       63  
                                 

Loss before income tax

    (3,298 )     (1,015 )     (9,557 )     (9,425 )

Income tax expense

    (24 )     (103 )     (66 )     (395 )
                                 

Loss from discontinued operations before disposal

    (3,322 )     (1,118 )     (9,623 )     (9,820 )

Gain on sale of subsidiary interests

    -       53,674       6,986       53,674  
                                 

Net income (loss) from discontinued operations

  $ (3,322 )   $ 52,556     $ (2,637 )   $ 43,854  

 

   

Nine months ended September 30,

 
   

2025

   

2026

 
   

(Unaudited)

   

(Unaudited)

 
                 

Net cash used in discontinued operating activities

  $ (8,881 )   $ (7,400 )

Net cash provided by discontinued investing activities

  $ 8,580     $ 3,769  

Net cash provided by discontinued financing activities

  $ 2,997     $ 3,864  

 

In connection with the Sale, the Company recorded a gain on the sale of subsidiary interests:

 

   

Gain recognized on the Sale

 

Fair value of consideration received

  $ -  

Add: Fair value of retained investment in SEED Disposal Group

    18,373  

Add: Carrying amount of noncontrolling interests in the disposal groups

    6,529  

Less: Carrying amount of net assets (liabilities) of the disposal groups

    (28,897 )

Add: Cumulative foreign currency translation adjustment reclassified to earnings

    (125 )

Gain on sale of subsidiary interests

  $ 53,674